Table 1.

Comparison of underlying disease, the effect of intrapulmonary rFVIIa therapy, and survival of DAH

Patient	Gender	Diagnosis	Pathogenesis of DAH	rFVIIa doses via BAL	Evaluation of rFVIIa effecta	Survival or cause of death
1	Male	Allo-HSCTb (CLL)	CMV, GvHD	3	Good	Septic shock and cardiorespiratory failure
2	Male	Neurosarcoidosis	Unknown	1	Excellent	Septic shock
3	Male	AML	Unknown	1	Excellent	Survived
4	Female	Wegener's granulomatosis	Unknown	1c	Good	Survived
5	Female	AIDS	Unknown	2	Good	Septic shock and respiratory failure
6	Male	Allo-HSCT (AML)	Unknown	1	Excellent	Survived

^aThe hemostatic effect was statistically significant (p = 0.031, McNemar's test). ^bNon-myeloablative allogeneic stem cell transplantation. ^cOne rFVIIa dose via BAL and, three days later when not intubated, subsequent three consecutive doses of rFVIIa via jet nebulizer. AML, acute myeloid leukemia; BAL, bronchoalveolar lavage; CLL, chronic lymphatic leukemia; CMV, cytomegalovirus; DAH, diffuse alveolar hemorrhage; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; rFVIIa, human recombinant activated factor VII.